GALT — GALECTIN THERAPEUTICS INC NEW

Ownership history in D.A. DAVIDSON & CO.  ·  48 quarters on record

This page tracks every 13F SEC filing in which D.A. DAVIDSON & CO. reported a position in GALECTIN THERAPEUTICS INC NEW (GALT). Data includes quarterly share count, position size as % of portfolio, estimated market value, and end-of-quarter stock price — sourced directly from SEC EDGAR 13F filings.

Peak position
0.09% (2014 Q2)
Avg. % of fund
0.03%
First filed
2013 Q4
Last filed
2025 Q3
Quarters held
48
Quarter Action Shares Change Chg % % of Fund Mkt Value Price (EOQ)
2025 Q3 UNCHANGED 10,000 — 0% 0.00% $42K $4.24
2025 Q2 UNCHANGED 10,000 — 0% 0.00% $21K $2.11
2025 Q1 REDUCED 10,000 -9,000 -47.4% 0.00% $12K $1.22
2024 Q4 REDUCED 19,000 -11,771 -38.3% 0.00% $25K $1.29
44 older quarters hidden  —  Sign in free or upgrade to Premium to see full history
% of Fund (quarterly)    GALT price (monthly, adj. close)

Other funds also holding GALT

As of 2025 Q4 — sorted by position size

Solutions 4 Wealth, Ltd 0.16% Vivaldi Capital Management LP 3Y 7Y 0.12% Fortis Capital Advisors, LLC 3Y 0.07% Argyle Capital Partners, LLC 0.04% GSA CAPITAL PARTNERS LLP 3Y 7Y 0.04% Tulsa Wealth Advisors, INC 0.03% 683 Capital Management, LLC 3Y 7Y 0.03% Geneos Wealth Management Inc. 3Y 0.02% Traynor Capital Management, Inc. 3Y 7Y 0.02% Wealthspire Advisors, LLC 3Y 7Y 0.02%
← Back to D.A. DAVIDSON & CO. Holdings